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Background: Nanoceria is used as a catalyst in diesel fuel, as an abrasive in printed 
circuit manufacture, and is being pursued as an anti-oxidant therapeutic. Objectives: 
To extend previous findings showing that there were no reductions of cerium in organs 
of the mononuclear phagocyte (reticuloendothelial) system up to 30 days after a single 
nanoscale ceria administration. Methods: An ~ 5% aqueous dispersion of citrate-
stabilized 30 nm ceria, synthesized and characterized in-house, or vehicle, was iv 
infused into rats terminated 1, 7, 30 or 90 days later. Cage-side observations were 
obtained daily; body weight weekly. Daily urinary and fecal cerium outputs were 
quantified for 2 weeks. Nine organs were weighed and samples collected from 14 
tissues/organs/systems, blood and cerebrospinal fluid for cerium determination. 
Histology and oxidative stress were assessed. Results: Less than 1% of the nanoceria 
was excreted in the first 2 weeks; 98% in feces. Body weight gain was initially impaired. 
Spleen weight was significantly increased in some ceria-treated groups, associated with 
abnormalities. Ceria was primarily retained in the spleen, liver and bone marrow. There 
was little decrease of ceria in any tissue over the 90 days. Granulomas were observed 
in the liver. Time-dependent oxidative stress changes were seen in the liver and spleen. 
Conclusions: Nanoscale ceria was persistently retained by organs of the mononuclear 
phagocyte system, associated with adverse changes. The results support concern 
about the long-term fate and adverse effects of inert nanoscale metal oxides that 








Engineered nanomaterials (ENMs) have potential to contribute to applications that could 
produce intended (e.g., drug and gene delivery) or unintended (e.g. occupational and 
environmental) exposure. Understanding potential ENM toxicity lags behind application 
development, as is usually the case for new technologies. Insufficient understanding of 
ENM hazards could lead to human health problems and decreased public acceptance.  
 
Ceria (cerium [Ce] oxide) ENMs have many current and potential commercial 
applications. Ceria is highly insoluble, including in phagolysosomal fluid at pH 4.5 (He et 
al., 2010) and abrasive, enabling its use in chemical-mechanical planarization 
(integrated circuit manufacture) (Feng et al., 2006). Most ceria applications capitalize on 
its redox activity, including as an oxygen sensor (Molin et al., 2008), diesel fuel catalyst 
(increases combustion and converts carbon monoxide to carbon dioxide) (Cassee et al., 
2011;  HEI, 2001;  Park et al., 2007), in fuel cells (Yuan et al., 2009), and for potential 
medical applications.  
 
Therapeutic ceria ENM applications are generally based on its ability to reduce reactive 
oxygen species (ROSs). Using many different cells in culture ceria, ENMs have been 
shown to reduce levels of H2O2, the superoxide radical, i-NOS, NF-κB, TNF-α, 
interleukins, and other ROS endpoints. It has been suggested that ceria ENMs have 
utility in the prevention and/or treatment of cancer, diabetic cardiomyopathy, diesel 
exhaust- and cigarette smoke-induced oxidative stress, radiation therapy side effects, 
retinal degeneration, stroke, and neurodegenerative disorders (Babu et al., 2010;  Chen 
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et al., 2006;  Colon et al., 2010;  D'Angelo et al., 2009;  Das et al., 2007;  Estevez et al., 
2011;  Hirst et al., 2009;  Niu et al., 2011;  Xia et al., 2008;  Younce et al., 2010). Ceria-
mediated ROS reduction may relate to its properties as a SOD mimetic and its catalase-
like activity (Korsvik et al., 2007;  Pirmohamed et al., 2010) and is perhaps attributed to 
Ce(III) rather than Ce(IV) (Celardo et al., 2011). Most of these studies were conducted 
in models of induced oxidative stress.  
 
On the other hand, there are reports of ceria-induced toxicity, indicated by decreased 
cell viability, glutathione, and DNA content; and increased LDH release, 
malondialdehyde production, and apoptosis (Auffan et al., 2009;  Brunner et al., 2006;  
Lin et al., 2006;  Park et al., 2008). Most of these studies were conducted in non-ROS 
stimulated cells. The reported effects of ceria ENM on non-mammalian organisms have 
generally been detrimental, including decreased growth, fertility, and survival; and 
increased lipofuscin accumulation and susceptibility to oxidative stress, shown in 
Pseudokirchneriella subcapitata (green algae), Synechocystis PCC6803 and Anabaena 
CPB4337 (cyanobactreria), E. coli, Daphnia magna, and C. elegans (Rodea-Palomares 
et al., 2011;  Roh et al., 2010;  Thill et al., 2006;  Van Hoecke et al., 2009;  Zeyons et 
al., 2009;  Zhang et al., 2010). These studies do not inform about the long-term effects 
and fate of ceria ENM in the intact mammal, the target of medical applications and a 




Nanoscale ceria was identified for toxicity evaluation by the NIEHS ILS, 2006) and 
OECD Environment Directorate (OECD, 2008). The need for in vivo studies that 
examine its biokinetics and toxicity was recently identified (Cassee et al., 2011).  
 
A few studies with ceria ENM have been conducted in the intact mammal. Reduced 
myocardial oxidative stress was seen in transgenic mice that display ischemic 
cardiomyopathy (Niu et al., 2007). Granulomatous inflammation was seen after 
pulmonary instillation and inhalation (Cho et al., 2010;  Srinivas et al., 2011). Intra-
vitreal injection reduced retinal vascular lesions (Zhou et al., 2011).  
 
Most therapeutic applications of ceria ENM will require systemic or pulmonary 
administration as its oral absorption is poor (~0.001%), although somewhat better from 
the lung (~0.1 to 1%) (He et al., 2010; Hirst et al., 2011; Yokel et al., submitted for 
publication). Translocation can occur from the lung (and potentially other sites of 
uptake) to blood and ultimately all organs (He et al., 2010). Therefore the fate of ceria 
that is introduced into, or reaches, blood needs to be better understood.  
 
Our previous research showed persistence in liver and spleen up to 30 days after 
systematic introduction of 5, 15, 30, and 55 nm ceria ENMs (Yokel et al., submitted for 
publication). Ceria increased the protein oxidation marker protein carbonyl (PC) levels in 
liver 30 days after 5 nm ceria ENM treatment. Ceria-containing macrophages were seen 
in the spleen and liver 30 days after 5 and 30 nm ceria ENMs, associated with hepatic 
10 
 
granulomas comprised of Kupffer cell cores, surrounding mononucleated cells, and CD3 
positive T lymphocytes (Tseng et al., submitted).  
 
The present study was conducted to test the hypotheses that a significant amount of 
ceria ENM persists in the mammal beyond 30 days and that adverse tissue changes 
seen 30 days after ceria administration progress. The objectives were to ascertain the 
distribution, translocation, elimination, and selected biological effects (including 
histopathology and oxidative stress) for 90 days after a single iv ceria ENM infusion. 
The iv route was selected to model the ceria that would enter systemic circulation after 
translocation from any uptake site, such as the lung, as well as its iv administration, as 




Materials and Methods 
Nanomaterial:  
A ~5% aqueous citrate-stabilized ceria dispersion was synthesized using a 
hydrothermal approach (Mai et al., 2005). It was citrate coated (capped) to prevent the 
agglomeration seen with uncoated ceria that occurs in high ionic strength solutions, 
such as blood (Xia et al., 2008). Citrate is a commonly used surface coating agent for 
ENMs, a component of blood (~ 100 µM in humans), and has been shown to have no 
effect on erythrocyte response to a silver ENM (Choi et al., 2011). Generally, a 20 ml 
aqueous mixture of 1 mmol cerium nitrate and 105 mmol sodium hydroxide were stirred 
for 0.5 h. This produced a milky suspension that was transferred into a Teflon-lined 
stainless steel bomb and heated at 180 °C for 24 h. The fresh white precipitate was 
then washed with deionized water three times followed by ethanol three times to 
remove free cerium and organic impurities. The wet precipitate was then dispersed into 
0.05 M citric acid aqueous solution with stirring overnight, followed by washing with 
water 5 times.  The resulting dispersion had a pH of 3.9. It was sterilized by autoclaving. 
To determine whether autoclaving affected the ceria ENM concentration, quadruplicate 
samples of the dosing material were prepared for Ce analysis before and after 
autoclaving. Eleven samples of the dosing material were digested by 2 methods and 
analyzed by inductively coupled plasma mass spectrometry (ICP-MS) to quantify ceria 
content (Yokel et al., 2009). It was 5.2 ± 0.1%. Based on the volumes infused the dose 
given the rats was ~ 87 mg ceria/kg. The autoclaved ceria ENM was iv infused without 





Ceria characterization:  
The morphology, crystallinity, and particle size distribution of highly diluted samples of  
the citrate-coated ceria ENM were determined in our laboratories using high resolution-
transmission electron microscopy (TEM)/scanning transmission electron microscopy 
and X–ray diffraction analyses/scanning TEM (200-keV field emission analytical 
transmission electron microscope [JEOL JEM-2010F, Tokyo, Japan] equipped with an 
Oxford energy dispersive X-ray spectrometer). The primary particle size was 
determined using Gatan software (DigitalMicrograph 3.7.1, Pleasanton, CA) by sizing 
110 particles. From the data of individual primary particle sizes measured from the TEM 
images, a number frequency cumulative distribution was constructed. The cumulative 
distribution was best described by a log-normal distribution model, characterized by a 
sample mean and a standard deviation. The data were well-described by a mono-modal 
distribution, e.g., one continuous distribution was observed with no significant 
secondary or tertiary peaks. The reported ‘average’ diameter of each sample 
was ( )µexp=aveD , where µ is the mean of the log-normal probability distribution, and the 
reported ‘standard deviation (SD)’ is the value from the fit of the log-normal distribution 
to the data. A number-based differential frequency distribution was constructed using 
the model coefficients. The ceria nanoparticles were crystalline and highly pure as 
determined by X–ray diffraction (Siemens 5000 diffractometer). Particle size distribution 
in aqueous dispersion was determined using dynamic light scattering (90Plus 
Nanoparticle Size Distribution Analyzer, Brookhaven Instruments Corp, Holtsville, NY). 
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The surface area of the dried powder was determined by isothermal nitrogen adsorption 
using a BET surface area analyzer (Tristar 3000; Micromeritics Instrument Corporation, 
Norcross, GA, USA). To indicate the stability of the ceria dispersion when infused into 
the rat, the zeta potential was measured using a Zetasizer nano ZS (Malvern 
Instruments, Worchestershire, UK). Since the ceria ENM had a hydrodynamic diameter 
< 200 nm, the Hückel approximation was used to calculate zeta potential from 
electrophoretic mobility. STEM images were acquired using the high resolution probe at 
2 Angstrom in a 2010F STEM outfitted with a URP pole piece, GATAN 2000 GIF, 
GATAN DigiScan II and EmiSpec EsVison software. The ceria ENM was analyzed prior 
to administration using electron energy loss spectroscopy (EELS) to determine its 
M4/M5 ratio as a measure of its original oxidative signature.   EELS measurements 
were performed using the 0.2 Angstrom probe, an alpha of 20 mrad, and a beta of 6 
mrad to estimate the Ce(III) vs. Ce(IV) oxidation states from the M4/M5 ratio, 
respectively. The interior of the 30 nm ceria ENM and the exterior particle surface were 
separately analyzed.  To estimate the extent of citrate surface coating the ceria ENM 
was washed at least three times with water before drying. Thermogravimetric analysis 
(Perkin-Elmer TGA7 Analyzer) was then performed to determine the weight loss of the 
citrate-coated ceria ENM from 150 to 300°C over which decomposition of citric acid 
occurs. The extent of citrate surface coating was estimated based on the assumption 
that the ceria ENM was spherical and had a uniform size. The free Ce concentration in 
the washed ceria ENM dispersion was determined using Amicon Ultra-4 centrifugal 
3000 molecular weight cut-off filter devices and centrifugation at 3000 g to obtain filtrate, 





The results of this study are from 31 male Sprague Dawley rats, weighing 300 ± 19 g 
(mean ± SD), purchased from Harlan, They were housed individually prior to study and 
after cannulae removal (a few days after the iv infusion) in the University of Kentucky 
Division of Laboratory Animal Resources facility under a 12:12 h light:dark cycle at 70 ± 
8°C and 30 to 70% humidity. The rats had ad lib access to 2018 Harlan diet and RO 
water.  Animal work was approved by the University of Kentucky Institutional Animal 
Care and Use Committee. The research was conducted in accordance with the Guiding 
Principles in the Use of Animals in Toxicology.  
 
Ceria administration: 
In initial studies, un-anesthetized rats were infused iv with ~100 mg ceria ENM 
dispersion/kg using described procedures (Yokel et al., 2009). Rats tolerated the ceria 
infusion well. Therefore the test doses were ~100 mg ceria/kg (found by analysis to be 
87 mg ceria/kg, equivalent to 70 mg Ce/kg) infused over 1 h, or water (controls for ceria 
vehicle) adjusted to pH 3.9, infused over 1 h. This large ceria ENM exposure was 
utilized to enhance our ability to detect Ce in multiple tissues and fluids up to 90 days 
after the single infusion. Fifteen rats were infused with vehicle and 16 with ceria. Three 
control and 3 ceria treated rats were terminated 1, 7, or 30 days after completion of the 
infusion. Six control and 7 ceria treated rats were terminated 90 days after the infusion. 
All rats were cage-side observed daily to assess respiratory, musculo-nervous, 
ophthalmic and other abnormalities (the presence of dyspnea, tachypnea, tremor, 
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ataxia, head tilt, hyperactivity, hypoactivity, lethargy, paralysis, opacity of the eyes, 
dilated/constricted pupils, exophthalmia, enophthalmia, conjunctivitis, abnormal 
secretions/crusting of the eyes, corneal ulcers, diarrhea, ruffled fur, urine staining, and 
other notable observations). Each was weighed weekly. Rats scheduled for termination 
at 7, 30, or 90 days were housed in metabolic cages from 3 days before until the 7th or 
14th day after infusion. Urine and feces were collected daily from 6 control and 8 ceria 
ENM-treated rats to 7 days and 6 control and 5 ceria ENM-treated rats to 14 days.   
 
Ceria distribution and elimination: 
Daily urine volume was determined. Daily feces weight was determined as the wet 
feces and after drying to constant weight. At termination the brain, lung, thymus, heart, 
spleen, liver, adrenal, right kidney, and right testis were rapidly removed and weighed. 
Samples were obtained for Ce analysis from brain cortex, lung, thymus, heart 
(horizontal medial cross-section), spleen (medial tip), liver (near tip of the larger of the 
two bifurcated lobes), adrenal, right kidney (medial cross-section), intestine (a 1 cm 
segment 5 to 6 cm below the pyloric sphincter), testis (internal issue), skeletal muscle 
from the right femur, skin (from the middle of the back), bone marrow (tibia), whole 
blood (vena cava), and cerebrospinal fluid (withdrawn from the cisternomedullary 
space). The skeletal system was cleaned by Dermestidea beetles, cleaned of beetle 
residue by placing the skeleton in deionized water in a Ziploc® bag which was sonicated 




Samples of each collected tissue and fluid, and skeletal system samples from the 
cranium, spinal column, ileac crest (pelvis), and femur (representative of the 
appendages) and the rat chow consumed by these subjects, were prepared and 
analyzed for Ce by ICP-MS; Agilent 7500cx, Santa Clara, CA, USA) as previously 
described, which reported the method detection limit (MDL) of Ce in tissue of 0.089 mg 
Ce/kg and 0.018 mg Ce/l in blood or serum samples (Yokel et al., 2009). The 
procedures to prepare and analyze the samples are described in the Supplemental 
Information. Cerium concentrations below the MDL were reported as 50% of the 
MDL. Organ/system Ce concentration in all tissues/fluids as well as mass amount of Ce 
and percent of the ceria dose in the rat were calculated; the latter from the organ weight 
or based on 0.02, 1.8, 50, 20, 3 and 7% of the body weight for the adrenal gland, 
intestine, skeletal muscle, skin, bone marrow, and blood, respectively.  The skeletal 
system was separated into 4 components (cranium, spinal column, pelvis, and femur) 
which constituted 21, 38, 10, and 31% of its weight, respectively.  
 
Tissue preparation and histological evaluation: After termination of ketamine-
anesthetized rats harvested tissue samples were immediately immersed in 10% neutral 
buffered formalin and subsequently processed by paraffin embedding for histopathology 
analysis. Sections (5 µm) were cut and stained with hematoxylin and eosin and 
examined for qualitative and quantitative changes. For plastic embedding, tissues were 
cut into 3 mm3 pieces, post fixed in osmium tetraoxide, dehydrated, and embedded in 
Araldite 502. One micron sections were cut and stained with toluidine blue. All sections 
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were coded and examined by an experienced histologist and an experimental 
pathologist.  
 
Oxidative stress assessment:  
Protein carbonyl (PC) levels, as a global marker for protein oxidation and oxidative 
stress, were measured in liver and spleen using a specific antibody and slot blot 
technique as described (Butterfield, 1997;  Sultana et al., 2005). The liver and spleen 
were examined because they had the highest ceria concentrations.   
 
Data and statistical analysis:  
Grubb’s test was used to identify outliers in fluid, tissue, urine and feces Ce results.  A 
two-way ANOVA was used to compare body weights of rats terminated 90 days after 
treatment, normalized to their treatment day weight.  Organ weights, not and normalized 
to body weight, were compared by one way ANOVAs followed by Tukey’s multiple 
comparison tests, and unpaired t tests. The percentage of the ceria dose in the liver, 
spleen, kidney, heart, lung, brain, thymus, and testis was calculated based on each rat’s 
whole organ weight times its Ce concentration, correcting for Ce as a percentage of 
ceria. Median pre-treatment 24 h urine and feces Ce excretion obtained from 24 rats 
was subtracted from post-treatment values of ceria-treated rats to obtain the excretion 
of Ce attributable to treatments. The concentration of Ce and percent of dose in all 
sampled tissues and fluids and of the four skeletal system regions were compared by 
two way ANOVAs and Bonferroni multiple comparisons. One-way ANOVAs with Tukey 
tests were also conducted to determine differences in the percent of dose across time in 
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each sampled tissue or fluid and across tissues and fluids at the same time. Results are 
reported as mean ± SD, except for the PC levels in ceria-treated rats which were 
normalized to their respective control samples and expressed as % mean ± SEM. 





HR-TEM/HR-STEM showed the ceria ENM was crystalline (its only known structure is 
face-centered cubic) (Figure 1A). It had Miller indices of (111), (220), and (311), and 
with lesser presence of (200), (222), and (400), based on XRD crystal structure linked to 
known morphology. Its average (and SD) primary particle diameter was 31.2 (17.1) nm. 
The particle size distribution was bimodal. The peaks were centered at 41 and 273 nm; 
the percentages of each peak were 100:0 (number basis) and 36:64 (volume basis). 
Figure 1B shows the fit of the lognormal model (continuous curve) to the cumulative 
distribution (number frequency basis). Figure 1C shows the differential distribution 
computed from the model coefficients.   Note that, for a log-normal distribution, the 
mean of the distribution, μ, is not the peak of the differential distribution, but is displaced 
to a slightly higher diameter. Primary ENM particles can agglomerate (self-associate) in 
aqueous dispersions, yielding particles that tend to associate with each other rather 
than the TEM grid (Figure 1A). Different weighting factors that can be used to estimate 
average ENM size, including number-based (typically the result of TEM diameter 
measurements), volume-based (which is dose-related as it links directly to the mass of 
ENM of a specific size), and intensity (the signal from the light scattering experiment). 
The bimodal distribution demonstrates that agglomeration occurred for this ENM. The 
BET-determined surface area was 15 m2/gm, which would correspond to an average 
diameter of 52 nm. The estimated differences between the TEM and BET methods 
suggest that this ENM may self-associate with one whole face to form agglomerates, 
reducing its apparent surface area. Some face-to-face agglomerates can be seen in 
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Figure 1A. The zeta potential in water at pH ~ 7.3 was -56 (± 8) mV. The EELS results 
show that the surface of the ENM had a slightly reduced valency at its outer rim and a 
more enhanced valency (less reduction) in the central (core) region. This was observed 
as a change in the height of the sharp intense peaks at the cerium M5 and M4 edges (~ 
883 and 900 eV).  A representative EELS line scan from the exterior surface towards 
the inner zone of the ceria shows the enrichment of Ce(III) at the particle rim (surface 
layer) (Figure 1D). The extent of surface citrate coating was ~18%. The free Ce content 




All ceria-treated rats survived for their assigned study duration. Daily cage-side 
observations revealed no adverse effects.  There was no significant difference in daily 
wet feces outputs during the first week between ceria-treated and control rats. The only 
significant differences in urine outputs were greater output on day 3 among the ceria-
treated rats terminated at 1 week compared to many of the other groups and a lower 
output on day 4 compared to some groups.  Ceria ENM-treated rats showed a reduced 
body weight gain shortly after ceria administration (Figure 2). ANOVA results showed 
significant effects of treatment and time but not a significant interaction. The spleen of 
many ceria-treated rats showed punctate white specs. The only organ showing a 
significant difference in weight between control and treated rats was the spleen.  This 
was not revealed by the one way ANOVA (P = 0.108), however 2-tailed unpaired t-tests 
showed the treated rats to have significantly heavier spleens at 1 and 30 days (non- and 
21 
 
normalized to body weight) and significantly lighter at 7 days (not normalized to body 
weight) (Figure 3).  
 
Ceria distribution and elimination: 
Grubb’s test revealed 6 outlier Ce concentration results, among 304 tissue/fluid x 
termination time x treatment conditions for the ceria ENM-treated rats.  Among the 283 
tissue/fluid samples from the control rats, 231 were below the MDL, vs. 19 of the 304 
from treated rats, which were mainly brain (all 3 at 1 week and 1 month and 3 at 3 
months) and CSF (2 at 1 day and 2 at 1 week).   
 
Baseline (pre-ceria ENM treatment) 24 h urinary and fecal Ce excretion medians were 
0.038 and 1.04 μg, respectively. One post Ce treatment feces value was on outlier. 
When pre-treatment 24 h median Ce excretion was subtracted from total Ce excretion 
post ceria ENM dosing, ~ 2 and 100 μg of ceria appeared in the urine and feces in the 
first 2 weeks, representing ~ 0.01 and 0.5% of the dose, respectively (Figure 4).  
 
Tissue/fluid Ce concentration results are shown in Figure 5A and expressed as a 
percentage of the ceria dose in Figure 5B. Brain cerium concentration, corrected for the 
cerium in the blood vessels of the brain, in concert with extensive light and electron 
microscopic observations, suggested very little ceria ENM crossed the blood-brain 
barrier into brain cells.  A 2-way ANOVA of Ce concentration across time and among 
sampled tissues and fluids F(3,14,42) = 2.9, 25.9 and 2.24 showed significant effects of 
time, site and interaction (P = 0.036, < 0.0001, and = 0.0001, respectively). Bonferroni 
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comparisons only showed a significant decrease of Ce in spleen from day 1 compared 
to days 7 and 30 followed by a significant increase from days 7 and 30 compared to day 
90. A 2-way ANOVA of the percent of the dose across time and among sampled tissues 
and fluids F(3,14,42) = 4.06, 56.2 and 2.48 showed significant effects of time, site and 
interaction (P = 0.008, < 0.0001, and < 0.0001 respectively). Bonferroni comparisons 
only showed reductions in the percent of the dose in liver and bone marrow over time 
and an increase in the spleen, but no differences among the sampled sites. The lack of 
other significant differences might be due to the large number of comparisons in this 
analysis. Therefore, one-way ANOVAs with Tukey tests of the percent of the dose in 
each sampled site over time were conduced. They revealed significant reductions in the 
heart (from day 1 to days 7, 30 and 90) and the brain (from day 1 to day 90).  When all 
sample sites were compared at a single time (1, 7, 30 or 90 days), liver was higher than 
all sites but bone marrow, and bone marrow was higher than all other sites at day1; liver 
and bone marrow were higher than all other sites at day 7; liver was higher than all sites 
except bone marrow at day 30; and liver was higher than all sites but spleen, spleen 
was higher than all sites but bone marrow, and bone marrow was higher than all other 
sites but blood at day 90. These results show little decrease of Ce in the sampled sites 
over time, much more ceria in the liver, bone marrow and spleen than other sites, and 
evidence to translocation to the spleen at day 90. Figure 6 shows the ceria in the 4 
skeletal system regions studied. Two-way ANOVAs showed significant effects of time 
and region for Ce concentration and percent of dose but not interaction (F(3,3,9), = 
3.82, 5.82, and 0.98 (P = 0.0157, 0.0018 and 0.47, respectively). The significant 
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differences are shown in Figure 6. The spinal column and pelvis had considerably more 
Ce than the femur and cranium.  
 
The mean rat chow Ce concentration was 0.22 mg Ce/kg. Given that Sprague Dawley 
rats eat ~ 5 g food/100 gm body weight daily 
(http://www.aceanimals.com/SpragueDawley.htms), the daily Ce intake from food of 
these rats would be ~ 4.4 μg, and over 90 days 0.3 mg, or less than 2% of the Ce in the 
87 mg ceria/kg iv dose. Cerium is poorly absorbed from the GI tract (Durbin et al., 1956;  
Gehlhaus et al., 2009;  Miller and Byrne, 1970), as is ceria ENM (He et al., 2010;  Hirst 
et al., 2011;  Park et al., 2009). Therefore, Ce in the rat chow did not significantly 
contribute to blood and tissue Ce levels.  
 
Liver, spleen, and bone marrow showed the most avid uptake and retention of ceria 
ENM. The ceria-containing Kupffer cells situated in the sinusoids became visible by light 
microscopy 1 day after infusion. Less visible was hepatocellular accumulation. The 
continued presence of ceria after the single vascular infusion was associated with 
hepatic granuloma formation first seen after 30 days that persisted in the 90 day 
samples in all ceria-infused rats. These intra-sinusoidal cellular agglomerates 
comprised a core of Kupffer cells surrounded by mononucleated cells. In spite of the 
granulomatous formation, hepatic parenchyma remained viable (Figure 7A). Occasional 
perivascular accumulation of lymphocytes was also observed and one T cell population 
in the granuloma was identified by CD3 immunohistochemistry. In the enlarged spleen, 
histological examination showed ceria-containing macrophages both in the red and 
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white pulp in 30 and 90 day samples (Figure 7B). In the brain, unlike systemic tissue 
rich in mononuclear phagocyte cells, light microscopy did not reveal cells with ceria 
accumulation in neurites or the microvessels in the hippocampus (Figure 7C) or the 
cerebellum (Figure 7D).  
 
Oxidative stress assessment: 
Protein carbonyl levels were increased significantly in liver 1, 7, and up to 30 d and later 
decreased significantly 90 days after ceria treatment (Figure 8A). On the other hand, PC 
levels were decreased significantly 1, 7, and 90 days after ceria treatment in spleen 







The present study utilized an established 90 day toxicity protocol (1, 7, 30, and 90 days) 
to study the short and longer term effects of a single dose of a nanoscale ENM, as was 
employed to study the effects of intratracheal nanoscale quartz instillation (Warheit et 
al., 2008). The study used an in-house synthesized 30 nm cubic ceria that was well 
characterized, as required by this journal and advised by many (Bouwmeester et al., 
2011;  Maynard et al., 2011;  Powers et al., 2009;  Sayes and Warheit, 2009).  
 
The present study extends prior work that showed persistence of nanoscale ceria in 
mice and rats for up to 7 and 14 days after its oral administration, 7 days after the last ip 
injection, 28 days after its intratracheal instillation, and 30 days after its systemic 
introduction (He et al., 2010;  Hirst et al., 2011;  Park et al., 2009;  Park et al., 2010; 
Yokel et al., submitted for publication). The present study extended the determination of 
ceria in the rat up to 90 days and determined ceria in several more tissues and fluids 
than previously reported (bone marrow, which is a major site of ceria ENM distribution, 
and adrenal, thymus, skin and cerebrospinal fluid), providing a more complete 
assessment of its fate. The use of a large ceria ENM dose enabled us to see cerium in 
all sampled tissues and fluids up to 90 days, in comparison to prior work, some of which 
employed lower doses. Additionally, this study employed both ICP-MS and electron 
microscopy to determine ceria distribution, providing insight into the subcellular 
localization of the ceria. By determining multiple endpoints in one study, namely ceria 
disposition and persistence, subcellular localization in selected tissues, safety as cage-
side observations, effects assessment including protein carbonyls as a major indicator 
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of oxidative stress and histological evaluation, and determination of the valence of 
nanoceria in vivo which has not been previously reported by anyone, this study enabled 
the interpretation of the temporal inter-relationship of these endpoints.  
 
The short-term reduction of body weight gain compared to controls has been previously 
observed after high dose intratracheal instillation of ceria ENM (~ 130 nm ceria given to 
mice (Park et al., 2010). Given the large dose of ceria ENM, body weight gain reduction 
is not unexpected. The lack of morbidity (observable clinical toxicity) and mortality over 
the 90 days shows this dose of the studied ceria ENM did not produce profound toxicity, 
although abnormal changes were observed in the liver and spleen, discussed below. 
Splenomegaly after ENM exposure was reported after iv administration of a 49 nm 
magnetite-dextran ENM (Okon et al., 2000), and seen 30 days after a single iv 
administration of 5, 15, and the same 30 nm ceria ENM (Yokel et al., submitted for 
publication). The cause of this finding will require further study. 
 
The very small clearance of ceria, nearly all into feces, during the first 2 weeks after 
ceria ENM administration has been previously noted, although the prior studies did not 
quantify urinary cerium excretion after oral, intratracheal, iv, or ip ceria ENM 
administration (He et al., 2010;  Hirst et al., 2011). Given the ceria ENM was not 
eliminated to any significant extent, its prolonged retention is not surprising. Ceria, as 
Ce, was detectible in all tissues and fluids sampled at 90 days. There was no 
appreciable clearance of the ceria ENM over the 90 days, which was mostly present as 
intracellular ceria agglomerations in mononuclear phagocyte system tissues. Of the 
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64% of the ceria ENM dose found in the sampled organs and fluid compartments 90 
days after its administration, 72% was in the liver, spleen and bone marrow.  This is 
consistent with the accumulation of other insoluble metal and metal oxide ENMs in the 
liver, spleen, and bone marrow, e.g. (Ballou et al., 2004;  Choi et al., 2007;  Fabian et 
al., 2008;  Moghimi et al., 2001). Given the lack of ceria ENM clearance, it is assumed 
that a single large ceria ENM dose would model tissue cerium levels after repeated, 
smaller, doses.  We have found that the percentage of the dose of a 5 nm ceria ENM in 
the liver is comparable after a single iv administration of 11 mg ceria/kg, 5 
administrations of this dose given over consecutive days, and a single administration of 
56 mg ceria/kg (unpublished results).  
 
Prior studies found granulomas in the lung 7 days and in lymphocytes 14 days after ~ 
130 nm ceria given intratracheally to mice (Park et al., 2010). Multifocal 
microgranulomas changes were seen in the lung by day 14 of daily head-and-nose-only 
inhalation of 15 to 30 nm ceria ENM and granulomatous changes were observed in the 
lung 28 days after ceria ENM instillation into lungs of rats (Cho et al., 2010;  Srinivas et 
al., 2011). Other than the observation of granulomas in a few rats that received the 
lowest of the 3 doses of silver ENM by inhalation (Sung et al., 2009), the current study 
seems to be the first report of granulomatous changes in the mammalian liver after 
metal or metal oxide ENM administration. No progression or diminution of the 
granulomatous changes in the liver was seen over the 90 days.  The long term fate and 




One of the mechanisms by which nanomaterials interact with biological systems is by 
generation of free radicals (Nel et al., 2006). Depending on the reactivity and half life of 
free radicals, they can interact with and damage proteins, lipids, and nucleic acids. 
Apart from other important cellular functions, proteins can function as antioxidant 
enzymes or molecules, which comprise the cellular defense against free radical-
mediated oxidative stress. The interaction between proteins and free radicals may 
change the 3D structure of proteins by oxidative modification of the protein backbone or 
amino acid residues (Stadtman, 2006). A change in its 3D structure may affect or inhibit 
protein functions. The extent of oxidative damage of a protein can be estimated by PC 
levels, a global marker for protein oxidation. Therefore, PC levels were measured in 
control and ceria-treated rat liver and spleen samples. Increased PC levels in liver were 
found at most time points examined. These results confirmed earlier findings on liver PC 
at 30 days following a single iv 5 nm ceria ENM infusion (Tseng et al., submitted). There 
are few in vitro and in vivo studies reporting hepatotoxicity of nanomaterials which also 
reported pro-oxidant effects of ENM treatment (Hussain et al., 2005;  Loh et al., 2010;  
Patlolla et al., 2011;  Sayes et al., 2005;  Yuan et al., 2011). Although many studies 
reported ENM accumulation in the spleen (Ballou et al., 2004;  Choi et al., 2007;  Fabian 
et al., 2008;  Moghimi et al., 2001), oxidative stress effects of ENM treatment were not 
investigated. A recent study reported no effect on inflammatory cytokine release from 
spleen microphages after magnetic Fe2O3 ENM treatment (Wang et al., 2011). In 
contrast to liver, PC levels were decreased in the spleen at each time point examined 
(but statistical significance for the results at 30 days was not reached).  This difference 
in response from liver and spleen cells to ceria ENM treatment may be due to 
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differences in the cellular types in these organs. Interestingly, after 90 days ceria ENM 
induced anti-oxidant effects in both organs. Consequently, our findings suggest that 
there is a time-dependence to the effects of ceria treatment with respect to peripheral 
organs. These effects may relate to the oxidation state of the ceria ENM (Celardo et al., 
2011;  Korsvik et al., 2007;  Pirmohamed et al., 2010), which we found to be enriched 
with Ce(III) at the particle surface in this study. As there is a very limited literature 
available on short term and long term effects of ENM treatments, it is difficult to discuss 
the variation in the oxidative stress response within an organ or from organ to organ. 
Therefore, short and long term effects of ENM treatment on redox status of liver and 
spleen are under investigation. 
 
Ceria is considered an inert material, from a solubility standpoint. However, due to its 
redox catalytic properties, it has significant chemical activities, for which it is used and 
being pursued in many applications, as noted in the Introduction. Its lack of solubility 
probably contributes to its persistence and its catalytic activity probably contributes to its 
effects on oxidative stress endpoints. It is unclear if the adverse effects seen in the liver 
and spleen are due to mechanical irritation from its presence or its chemical (catalytic) 
activity.  These results further support the concern about inert nanoscale metal oxides 
that are introduced into, or reach, systemic circulation, from which they can distribute 
throughout the body, and result in persistent retention and potential adverse effects in 




The present results provide information assessing the health effects of nanoceria.  
Although much was learned about the distribution and retention of ceria ENM and 
concurrent effects, there are limitations to this, and any, study. One is the use of a 
laboratory-generated ENM for study, which might not be representative of commercial 
nanoceria. Indeed, our initial study utilized a commercial ceria ENM; however we were 
unable to obtain from the supplier some characterization information needed to fully 
understand the ENM (Yokel et al., 2009). This led to our decision to manufacture and 
characterize in house our ENM study materials, enabling us to better understand the 
material we are studying. As noted in the Introduction, nanoceria is utilized in multiple 
applications. These would represent different physicochemical forms, with different 
surface capping agents, and in different dispersing media, or as solids.  It is not 
feasible, time-wise or economically, to characterize well all nanomaterials (Choi et al., 
2009), making it necessary to extrapolate or use other approaches such as tiered 
testing systems and grouping (banding) similar ENMs. For this study we selected a 
ceria ENM size that appears to be in the range where ENMs are most different from the 
effects of their solution or bulk scale components, based on protein binding (Nel et al., 
2009), cell uptake (Chithrani et al., 2006), and induction of acellular oxidative stress 
(Jiang et al., 2008).  It is anticipated that ceria ENM solubility would not be influenced by 
size, which relates to persistence, a major focus of this study. We must also realize that 
ENMs are highly reactive and therefore their composition can change in the body of the 
organism exposed to them, e.g. by opsonization, and in the environment. It is important 
to begin investigations on the kinetics and effects of nanomaterials of known 
composition. The present results add to prior knowledge about ceria ENMs and identify 
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some of the issues that warrant further study to more fully characterize their health 
effects.   
 
Conclusions: A single ceria ENM administration initially reduced body weight gain. 
Cerium excretion following ceria ENM infusion was 98% in the feces and very slow, 
resulting in elimination of < 1% of the dose in the first two weeks. Spleen weight was 
greater at most times after ceria ENM administration, associated with visual and 
microscopic evidence of abnormality. Nanoscale ceria was retained in mononuclear 
phagocyte system tissues from which there was little clearance over 90 days, 
supporting the hypothesis that a significant amount of ceria ENM persists in the 
mammal well beyond 30 days. However, the lack of morbidity, mortality or significant 
progression (or regression) of adverse changes in the liver and spleen fail to support the 
hypothesis of progression of untoward effects beyond 30 days. The long term effects of 
nanoscale ceria that enters cells warrants investigation, considering the near 
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Figure 1. Panel A: TEM image of 30 nm ceria showing cubic particles. The insert in the 
top right hand corner is an electron diffraction pattern verifying the ceria crystallinity. 
Panels B and C: Primary particle size distribution of the ceria ENM, as determined by 
TEM, showing cumulative and differential frequency distributions. Panel B shows the 
TEM size distribution data as points and a lognormal model as a continuous curve. 
Panel C shows the differential distribution as represented by the lognormal model. 
Panel D: HR-STEM image of the as-produced ceria ENM.  EELS analyses were 
conducted along the indicated trace line (arrow) starting at the exterior rim or surface 
layer and ending in the core region. The computed M4/M5 ratio shows the change in the 
oxidation state.   
 
Figure 2. Body weight of control and ENM-ceria treated rats after treatment. 
 
Figure 3. Spleen weight, as a percent of body weight. * = significantly different from 
control at same time by t-test. 
 
Figure 4. Daily urine (A) and fecal (B) Ce excretion of 5 ceria-treated rats, as mass 
amount (left panels) and as a percentage of the dose (right panels). Note the 50-fold 





Figure 5. Cerium concentration (A) and percent of the dose (B) in tissues, blood and 
cerebrospinal fluid (CSF).  Skeletal system Ce concentration is the mean of the 4 
regions and % of dose is the sum. 
 
Figure 6. Cerium concentration (A) and percent of the dose (B) in the 4 skeletal system 
regions. Significantly different, p < 0.05, 0.01, 0.001 and 0.0001, *, **, *** and ****, 
respectively. 
 
Figure 7. Histology of liver, spleen, hippocampus, and cerebellum 90 days after ceria 
ENM infusion.  Panel A shows the normal appearing liver with a granuloma formation. 
Panel B was taken from the white pulp of a spleen showing phagocytic cells with ceria 
particulates. Panel C illustrates a CA1 pyramidal cell and adjacent small vessel (arrow), 
both free of ceria. Panel D shows cerebellar tissue and the absence of ceria in both the 
neuronal and vascular components (arrow).  
 
Figure 8: Panel A histogram represents protein carbonyl levels in liver 1 day, 7 days, 30 
days and 90 days after ceria treatment measured in control and ceria treated rats. 
Significant difference reported for **p< 0.01 and ***p< 0.001. Panel B histogram 
represents protein carbonyl levels in spleen, 1 day, 7 days, 30 days and 90 days after 
ceria treatment measured in control and ceria treated rats. Significant difference 
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